Item 8.01. Other Events.
On January 6, 2022, 2seventy bio, Inc. issued a press release announcing that it
has entered into an option and license agreement with Novo Nordisk for the joint
research and development of an in vivo gene editing treatment for hemophilia A
and that it has entered into an agreement with Genevant Sciences for access to
Genevant's industry-leading LNP technology platform for use in the collaboration
with Novo Nordisk. A copy of such press release is filed as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
No.                                               Description
99.1                 Press Release of 2seventy bio, Inc., dated January 6, 2022.

__________________

© Edgar Online, source Glimpses